Causes
Chronic fatigue syndrome, also called myalgic encephalomyelitis, is understood as a complex, multisystem disorder rather than a single narrowly defined disease. Research reviewed by Anthony Komaroff at Harvard Medical School highlights patterns of immune dysregulation, autonomic nervous system abnormalities, and metabolic disturbances that together can produce profound, long-lasting fatigue. The Institute of Medicine concluded that the condition is a serious organic illness with hallmark features such as post-exertional malaise, meaning symptoms worsen after physical or mental exertion. These findings do not point to a single universal cause; instead, they suggest multiple overlapping mechanisms that differ among patients. Viral triggers, including Epstein-Barr virus and other common infections, have been implicated in many onset histories, and ongoing studies by Avindra Nath at the National Institute of Neurological Disorders and Stroke examine persistent immune and neurological changes after infection. The Centers for Disease Control and Prevention documents that onset can follow infections, physical stressors, or appear gradually, reinforcing the view that heterogeneous triggers act on vulnerable biological systems.
Treatment approaches
There is no single cure and no medication approved specifically for chronic fatigue syndrome. Clinical practice and guidelines emphasize symptom management and tailored rehabilitation. Pacing—adjusting activity to stay within energy limits—is a core strategy to reduce relapses from post-exertional malaise. Cognitive behavioral therapy and graded exercise therapy were promoted in past guidelines after the PACE trial led by Peter White at Queen Mary University of London reported modest benefits, but later critique and reanalyses raised questions about trial methods and applicability, and many patient groups emphasize caution. As a result, contemporary guidance from specialists and public health agencies focuses on individualized care: management of sleep and pain, treatment of orthostatic intolerance or other autonomic symptoms, and careful, patient-led activity planning. Pharmacologic approaches target specific symptoms, such as sleep disturbance or pain, rather than the underlying condition. Ongoing clinical trials and mechanistic studies aim to identify targeted therapies once reliable biomarkers and causal pathways are confirmed.
Consequences and social context
The consequences of chronic fatigue syndrome extend beyond medical symptoms to social, economic, and cultural dimensions. The illness frequently reduces ability to work, participate in education, or maintain social roles, and patients often confront skepticism because fatigue is invisible and fluctuating. Women are disproportionately affected, which intersects with historical biases in diagnosing and treating conditions that primarily affect women. Geographic disparities in recognition and resources mean access to knowledgeable specialists varies by territory and health system. The recent emergence of post-viral syndromes after COVID-19 has increased research funding and public awareness; NIH initiatives and academic centers are expanding investigations to better define pathophysiology and to develop objective measures, as discussed by researchers at the National Institutes of Health. Improved understanding will be necessary to reduce stigma, guide policy for disability and workplace accommodations, and create effective, evidence-based treatments that address the biological causes rather than merely managing symptoms. Progress depends on rigorous, transparent research and respectful, patient-centered clinical care.